Miracle Mile Advisors LLC Boosts Position in Johnson & Johnson (NYSE:JNJ)

Miracle Mile Advisors LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 86.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 119,200 shares of the company’s stock after purchasing an additional 55,200 shares during the period. Miracle Mile Advisors LLC’s holdings in Johnson & Johnson were worth $17,239,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in JNJ. Horizon Wealth Management LLC increased its position in shares of Johnson & Johnson by 13.8% during the fourth quarter. Horizon Wealth Management LLC now owns 1,683 shares of the company’s stock worth $243,000 after purchasing an additional 204 shares in the last quarter. Sunflower Bank N.A. increased its position in Johnson & Johnson by 2.4% during the fourth quarter. Sunflower Bank N.A. now owns 10,572 shares of the company’s stock worth $1,529,000 after buying an additional 244 shares during the period. Davis Investment Partners LLC lifted its stake in Johnson & Johnson by 31.6% in the fourth quarter. Davis Investment Partners LLC now owns 4,103 shares of the company’s stock valued at $583,000 after buying an additional 985 shares during the last quarter. Elevated Capital Advisors LLC grew its position in shares of Johnson & Johnson by 33.3% during the fourth quarter. Elevated Capital Advisors LLC now owns 4,978 shares of the company’s stock worth $720,000 after acquiring an additional 1,244 shares during the last quarter. Finally, Marshall & Sullivan Inc. WA increased its holdings in shares of Johnson & Johnson by 1.6% in the 4th quarter. Marshall & Sullivan Inc. WA now owns 30,155 shares of the company’s stock valued at $4,361,000 after acquiring an additional 474 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

Several research analysts have issued reports on JNJ shares. Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Wolfe Research began coverage on Johnson & Johnson in a research report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price target on the stock. Morgan Stanley increased their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 16th. StockNews.com cut Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 7th. Finally, Royal Bank of Canada lifted their price objective on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $174.71.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.7 %

Shares of NYSE JNJ opened at $144.50 on Tuesday. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45. The firm has a 50-day moving average price of $149.39 and a 200 day moving average price of $156.10. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market capitalization of $347.90 billion, a price-to-earnings ratio of 20.91, a price-to-earnings-growth ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The business had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the previous year, the company earned $2.66 EPS. The company’s quarterly revenue was up 5.2% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.43%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.